| [September 29, 2016] |
 |
Tarveda to Present at North American Neuroendocrine Tumor Society (NANETS) Symposium
Tarveda
Therapeutics, Inc., a biopharmaceutical company discovering and
developing Pentarins™ as a new class of targeted anti-cancer medicines,
today announced that the company will present at the 2016 North American
Neuroendocrine Tumor Society (NANETS) Symposium, September 30 - October
1, at the Jackson Lake Lodge, Grand Teton National Park, in Jackson,
Wyoming.
Dr. Richard Wooster, President, Research & Development and Chief
Scientific Officer, will present a poster at the meeting titled "The
Pentarin Miniaturized Drug Conjugate PEN-221 Targets the Potent
Cytotoxic DM1 to Somatostatin Receptor 2 Expressing Cancers". The poster
will be on display beginning Friday, September 30, at 12:30 p.m. MST.
PEN-221 is Tarveda's lead Pentarin that consists of a peptide ligand
that is highly selective for the somatostatin receptor SSTR2. This
somatostatin receptor is overexpressed on the surface of cancer cells in
a variety of neuroendocrine cancers, including small cell lung cancer.
The targeting ligand is chemically linked in a unique and optimized
fashion to the potent cell-killing payload DM1. In preclinical studies,
PEN-221 ha demonstrated the desired pharmacokinetics and deep tumor
penetration with complete tumor regressions in multiple, hard to treat
xenograft cancer models and has demonstrated superiority to the clinical
standard of care. Tarveda is advancing PEN-221 to enter the clinic in
2016.
About Pentarins™
Pentarins are miniaturized drug conjugates
that represent a novel approach for the application of drug conjugates
to the treatment of cancer. Tarveda applies its proprietary suite of
technologies to create Pentarins comprised of a targeting ligand
conjugated to a potent cell-killing agent through a chemical
linker. Pentarins are designed to overcome the biological barriers that
limit therapeutic effectiveness against solid tumors. Together, the
components of Tarveda's Pentarins have distinct yet synergistic
anticancer capabilities: the small size of Pentarins allows for
effective penetration and distribution into the tumor tissue, the
ligand's targeting ability allows for specific binding to tumor cells,
and the cell-killing payload is released inside the cancer cells for
efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc.,
is a biopharmaceutical company discovering and developing Pentarins™ as
a new class of targeted anti-cancer medicines to advance the treatment
of patients with solid tumor cancers. Tarveda's lead Pentarin drug
candidate, PEN-221, is a miniaturized biologic drug conjugate that
targets the somatostatin receptor for treatment of patients with
neuroendocrine cancers including small-cell lung cancer. Tarveda is also
advancing its HSP90 drug conjugate platform with lead PEN-866, which is
a drug conjugate that comprises an HSP90 ligand conjugated to SN-38, the
highly-potent, active metabolite of irinotecan. Tarveda's strategy
includes developing its own proprietary Pentarins as well as applying
the Pentarin platform to enhance the effectiveness of the targeting
moieties and novel payloads of pharmaceutical collaborators. Tarveda has
attracted top-tier investors including Novo A/S, New Enterprise
Associates, Flagship Ventures, NanoDimension, and Eminent Venture
Capital. www.tarveda.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005395/en/
[ Back To TMCnet.com's Homepage ]
|
